EMEA-000689-PIP01-09-M09
Key facts
| Invented name |
|
| Active substance |
exenatide
|
| Therapeutic area |
Endocrinology, -gynacology-fertility-metabolism
|
| Decision number |
P/0017/2020
|
| PIP number |
EMEA-000689-PIP01-09-M09
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of type II diabetes mellitus
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
AstraZeneca AB (Sweden)
Tel. +46 8553 27591 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|